On Thursday, Avid Bioservices (NASDAQ:CDMO) experienced a shift in stock rating as RBC Capital downgraded the company from Outperform to Sector Perform. This adjustment came alongside a price target increase to $12.50, up from the previous target of $12.00. The rating change is a response to the recent announcement that Avid Bioservices has agreed to be acquired by GHO Capital Partners (WA:CPAP) and Ampersand Capital Partners.
The acquisition deal is valued at approximately $1.1 billion, translating to $12.50 per share, which is roughly 6.3 times the consensus FY25 revenue. The all-cash transaction is anticipated to be finalized in the first quarter of 2025. According to RBC Capital, the deal received unanimous support from Avid's Board after considering various alternatives, and the valuation is seen as reasonable and in line with recent price targets.
RBC Capital's analyst noted that the expected closure of the transaction at the stated price is due to the Board's thorough evaluation of options and the deal's valuation, which aligns with the market's expectations. The new price target reflects this anticipated acquisition price, justifying the modest increase from the prior target.
Avid Bioservices specializes in biopharmaceutical development and manufacturing services. The acquisition by private equity firms GHO Capital Partners and Ampersand Capital Partners is set to take the company into a new chapter of ownership, pending the completion of the deal as projected.
In other recent news, Avid Bioservices has reported significant changes to its executive compensation framework, including the expansion of its 2018 Omnibus Incentive Plan and the amendment of its 2010 Employee Stock Purchase Plan (ESPP). The company has also reported a 6% revenue increase to $40.2 million in the first quarter of fiscal year 2025, despite a net loss of $5.5 million. Analysts from KeyBanc have maintained a positive outlook on Avid Bioservices, reiterating an Overweight rating.
In addition, the company anticipates growth in adjusted EBITDA and margins, with a potential 40% to 60% increase in incremental revenue. The majority of new projects came from new customers, indicating a diversifying client base. Furthermore, Avid Bioservices has received stockholder endorsement for the expansion of its 2018 Omnibus Incentive Plan and the amendment of its ESPP.
These recent developments reflect Avid Bioservices' commitment to aligning the interests of its executives with those of its shareholders and ensuring the ability to attract and retain top talent. The company's focus on enhancing its compensation strategies comes at a time when it is poised for growth in the pharmaceutical preparations industry. The potential impact of the BioSecure Act was also discussed, which if enacted, could compel U.S-based customers to seek domestic Contract Development and Manufacturing Organizations (CDMOs) over international providers.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Avid Bioservices' (NASDAQ:CDMO) financial position and market performance, providing context to the acquisition announcement and rating change. The company's market capitalization stands at $700.47 million, reflecting its current valuation in the market.
InvestingPro Tips highlight that Avid Bioservices has shown a significant return over the last week, with a 10.24% price total return. This recent uptick aligns with the announcement of the acquisition and the subsequent rating adjustment by RBC Capital. Additionally, the company has demonstrated strong performance over longer periods, with a substantial 87.05% price total return over the past year and a 25.34% return over the last six months.
However, it's important to note that Avid Bioservices faces some financial challenges. The company is not profitable over the last twelve months, with a negative P/E ratio of -4.86. This aligns with another InvestingPro Tip indicating that analysts do not anticipate the company to be profitable this year. These factors may have influenced the decision to pursue an acquisition, potentially seeking to leverage the resources and expertise of the acquiring firms to improve profitability.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and insights that could be valuable in understanding the full picture of Avid Bioservices' financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.